NCT04073498View on ClinicalTrials.gov

The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 14, 2019

Primary Completion Date

September 26, 2024

Study Completion Date

September 26, 2024

Conditions
Hemophilia aHemophilia B
Interventions
DRUG

SerpinPC

Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

DRUG

Placebo

Matching placebo administered by SC injection according to cohort dosing instructions.

Trial Locations (3)

0112

Arensia Clinical Research Unit, Tbilisi

Unknown

Arensia Clinical Research Unit, Chisinau

CF48 4DR

Simbec Research Ltd, Merthyr Tydfil

Sponsors

Lead Sponsor

ApcinteX Ltd
All Listed Sponsors
collaborator

Centessa Pharmaceuticals plc

INDUSTRY

lead

ApcinteX Ltd

INDUSTRY